ABSTRACT
SRT1720, a sirtuin1-activator, and metformin (MET), an antidiabetic drug, confer health and life-span benefits when administered individually. It is unclear whether combination of the two compounds could lead to additional benefits. Groups of 56-week-old C57BL/6J male mice were fed a high-fat diet (HFD) alone or supplemented with either SRT1720 (2 g/kg food), a high dose of MET (1% wt/wt food), or a combination of both. Animals were monitored for survival, body weight, food consumption, body composition, and rotarod performance. Mice treated with MET alone did not have improved longevity, and life span was dramatically reduced by combination of MET with SRT1720. Although all groups of animals were consuming similar amounts of food, mice on MET or MET + SRT1720 showed a sharp reduction in body weight. SRT1720 + MET mice also had lower percent body fat combined with better performance on the rotarod compared to controls. These data suggest that co-treatment of SRT1720 with MET is detrimental to survival at the doses used and, therefore, risk-benefits of combining life-span-extending drugs especially in older populations needs to be systematically evaluated.
Subject(s)
Heterocyclic Compounds, 4 or More Rings/pharmacology , Longevity/drug effects , Metformin/pharmacology , Animals , Body Composition , Body Weight , Diet, High-Fat , Heterocyclic Compounds, 4 or More Rings/administration & dosage , Male , Metformin/administration & dosage , Mice , Mice, Inbred C57BL , Models, Animal , Sirtuin 1ABSTRACT
Caloric restriction (CR) is the most potent nonpharmacological intervention known to both protect against carcinogenesis and delay aging in laboratory animals. There is a growing number of anticarcinogens and CR mimetics that activate NAD(P)H:quinone oxidoreductase 1 (NQO1). We have previously shown that NQO1, an antioxidant enzyme that acts as an energy sensor through modulation of intracellular redox and metabolic state, is upregulated by CR. Here, we used NQO1-knockout (KO) mice to investigate the role of NQO1 in both the aging process and tumor susceptibility, specifically in the context of CR. We found that NQO1 is not essential for the beneficial effects of CR on glucose homeostasis, physical performance, metabolic flexibility, life-span extension, and (unlike our previously observation with Nrf2) chemical-induced tumorigenesis.
Subject(s)
Body Composition , Caloric Restriction/adverse effects , Longevity , NAD(P)H Dehydrogenase (Quinone)/metabolism , Neoplasms, Experimental/prevention & control , Oxidative Stress , Animals , Biomarkers, Tumor/metabolism , Carcinogenesis , Immunoblotting , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasms, Experimental/etiology , Neoplasms, Experimental/metabolismABSTRACT
Calorie restriction (CR) is the most robust non-genetic intervention to delay aging. However, there are a number of emerging experimental variables that alter CR responses. We investigated the role of sex, strain, and level of CR on health and survival in mice. CR did not always correlate with lifespan extension, although it consistently improved health across strains and sexes. Transcriptional and metabolomics changes driven by CR in liver indicated anaplerotic filling of the Krebs cycle together with fatty acid fueling of mitochondria. CR prevented age-associated decline in the liver proteostasis network while increasing mitochondrial number, preserving mitochondrial ultrastructure and function with age. Abrogation of mitochondrial function negated life-prolonging effects of CR in yeast and worms. Our data illustrate the complexity of CR in the context of aging, with a clear separation of outcomes related to health and survival, highlighting complexities of translation of CR into human interventions.
Subject(s)
Aging/metabolism , Energy Intake , Sex Characteristics , Aging/genetics , Animals , Autophagy/genetics , Biomarkers/metabolism , Caloric Restriction , Cluster Analysis , Energy Intake/genetics , Female , Gene Expression Profiling , Gene Expression Regulation , Glucose/metabolism , Homeostasis/genetics , Hydrogen Sulfide/metabolism , Islets of Langerhans/anatomy & histology , Liver/metabolism , Liver/ultrastructure , Longevity/genetics , Longevity/physiology , Male , Metabolome , Metabolomics , Mice , Mice, Inbred Strains , Mitochondria/metabolism , Phenotype , Proteasome Endopeptidase Complex/metabolism , Ubiquitin/metabolismABSTRACT
The prevention or delay of the onset of age-related diseases prolongs survival and improves quality of life while reducing the burden on the health care system. Activation of sirtuin 1 (SIRT1), an NAD(+)-dependent deacetylase, improves metabolism and confers protection against physiological and cognitive disturbances in old age. SRT1720 is a specific SIRT1 activator that has health and lifespan benefits in adult mice fed a high-fat diet. We found extension in lifespan, delayed onset of age-related metabolic diseases, and improved general health in mice fed a standard diet after SRT1720 supplementation. Inhibition of proinflammatory gene expression in both liver and muscle of SRT1720-treated animals was noted. SRT1720 lowered the phosphorylation of NF-κB pathway regulators in vitro only when SIRT1 was functionally present. Combined with our previous work, the current study further supports the beneficial effects of SRT1720 on health across the lifespan in mice.
Subject(s)
Heterocyclic Compounds, 4 or More Rings/metabolism , Sirtuin 1/metabolism , Animals , Diet , Longevity , Male , Mice , Mice, Inbred C57BL , Sirtuin 1/genetics , Survival Analysis , TranscriptomeABSTRACT
Obesity is associated with a chronic, low-grade, systemic inflammation that may contribute to the development of insulin resistance and type 2 diabetes. Resveratrol, a natural compound with anti-inflammatory properties, is shown to improve glucose tolerance and insulin sensitivity in obese mice and humans. Here, we tested the effect of a 2-year resveratrol administration on proinflammatory profile and insulin resistance caused by a high-fat, high-sugar (HFS) diet in white adipose tissue (WAT) from rhesus monkeys. Resveratrol supplementation (80 and 480 mg/day for the first and second year, respectively) decreased adipocyte size, increased sirtuin 1 expression, decreased NF-κB activation, and improved insulin sensitivity in visceral, but not subcutaneous, WAT from HFS-fed animals. These effects were reproduced in 3T3-L1 adipocytes cultured in media supplemented with serum from monkeys fed HFS ± resveratrol diets. In conclusion, chronic administration of resveratrol exerts beneficial metabolic and inflammatory adaptations in visceral WAT from diet-induced obese monkeys.
Subject(s)
Adipose Tissue, White/drug effects , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Diet, High-Fat , Signal Transduction/drug effects , Stilbenes/pharmacology , Adipocytes/cytology , Adipocytes/drug effects , Adipocytes/metabolism , Adipose Tissue, White/metabolism , Animals , Carbohydrates , Cell Line , Inflammation/metabolism , Insulin/blood , Insulin/metabolism , Macaca mulatta/metabolism , Male , Mice , NF-kappa B/metabolism , Obesity/etiology , Obesity/metabolism , Resveratrol , Sirtuin 1/metabolism , Transcriptome , Viscera/metabolism , Viscera/pathologyABSTRACT
Metformin is a drug commonly prescribed to treat patients with type 2 diabetes. Here we show that long-term treatment with metformin (0.1% w/w in diet) starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Treatment with metformin mimics some of the benefits of calorie restriction, such as improved physical performance, increased insulin sensitivity, and reduced low-density lipoprotein and cholesterol levels without a decrease in caloric intake. At a molecular level, metformin increases AMP-activated protein kinase activity and increases antioxidant protection, resulting in reductions in both oxidative damage accumulation and chronic inflammation. Our results indicate that these actions may contribute to the beneficial effects of metformin on healthspan and lifespan. These findings are in agreement with current epidemiological data and raise the possibility of metformin-based interventions to promote healthy aging.
Subject(s)
Health , Longevity/drug effects , Metformin/pharmacology , AMP-Activated Protein Kinases , Animals , Antioxidants/pharmacology , Biomarkers/blood , Caloric Restriction , Electron Transport/drug effects , Enzyme Activation/drug effects , Inflammation/blood , Inflammation/drug therapy , Inflammation/pathology , Male , Metformin/therapeutic use , Mice , Mice, Inbred C57BL , Mitochondria/drug effects , Mitochondria/metabolism , Survival Analysis , Transcriptome/drug effects , Transcriptome/geneticsABSTRACT
A 45-year-old woman presented to the emergency department with a 2-day history of severe left shoulder pain made worse with movement. Emergency department (ED) bedside point-of-care static and dynamic ultrasound examination of the supraspinatus tendon revealed supraspinatus tendon calcification with impingement syndrome, and the patient was urgently referred to orthopedics after ED pain control was achieved. Bedside shoulder and supraspinatus tendon evaluation with static and dynamic ultrasonography can assist in the rapid diagnosis of supraspinatus tendon calcification and supraspinatus tendon impingement syndrome in the emergency department.
ABSTRACT
Sirt1 is an NAD(+)-dependent deacetylase that extends lifespan in lower organisms and improves metabolism and delays the onset of age-related diseases in mammals. Here we show that SRT1720, a synthetic compound that was identified for its ability to activate Sirt1 in vitro, extends both mean and maximum lifespan of adult mice fed a high-fat diet. This lifespan extension is accompanied by health benefits including reduced liver steatosis, increased insulin sensitivity, enhanced locomotor activity and normalization of gene expression profiles and markers of inflammation and apoptosis, all in the absence of any observable toxicity. Using a conditional SIRT1 knockout mouse and specific gene knockdowns we show SRT1720 affects mitochondrial respiration in a Sirt1- and PGC-1α-dependent manner. These findings indicate that SRT1720 has long-term benefits and demonstrate for the first time the feasibility of designing novel molecules that are safe and effective in promoting longevity and preventing multiple age-related diseases in mammals.
Subject(s)
Heterocyclic Compounds, 4 or More Rings/pharmacology , Longevity/drug effects , Obesity/physiopathology , Animals , Apoptosis/drug effects , Body Composition/drug effects , Dietary Fats/administration & dosage , Gene Expression/drug effects , Glucose/metabolism , Homeostasis/drug effects , Liver/drug effects , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Pancreas/drug effectsABSTRACT
The societal impact of obesity, diabetes, and other metabolic disorders continues to rise despite increasing evidence of their negative long-term consequences on health span, longevity, and aging. Unfortunately, dietary management and exercise frequently fail as remedies, underscoring the need for the development of alternative interventions to successfully treat metabolic disorders and enhance life span and health span. Using calorie restriction (CR)-which is well known to improve both health and longevity in controlled studies-as their benchmark, gerontologists are coming closer to identifying dietary and pharmacological therapies that may be applicable to aging humans. This review covers some of the more promising interventions targeted to affect pathways implicated in the aging process as well as variations on classical CR that may be better suited to human adaptation.